Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neelima Denduluri

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Pageof 6